Literature DB >> 9892017

Interaction of the putative androgen receptor-specific coactivator ARA70/ELE1alpha with multiple steroid receptors and identification of an internally deleted ELE1beta isoform.

P Alen1, F Claessens, E Schoenmakers, J V Swinnen, G Verhoeven, W Rombauts, B Peeters.   

Abstract

Steroid-regulated gene transcription requires the coordinate physical and functional interaction of hormone receptors, basal transcription factors, and transcriptional coactivators. In this context ARA70, previously called RFG and ELE1, has been described as a putative coactivator that specifically enhances the activity of the androgen receptor (AR) but not that of the glucocorticoid receptor (GR), the progesterone receptor, or the estrogen receptor (ER). Here we describe the cloning of the cDNA for ELE1/ARA70 by RT-PCR from RNA derived from different cell lines (HeLa, DU-145, and LNCaP). In accordance with the previously described sequence, we obtained a 1845-bp PCR product for the HeLa and the LNCaP RNA. Starting from T-47D RNA, however, an 860-bp PCR product was obtained. This shorter variant results from an internal 985-bp deletion and is called ELE1beta; accordingly, the longer isoform is referred to as ELE1alpha. The deduced amino acid sequence of ELE1alpha, but not that of ELE1beta, differs at specific positions from the one previously published by others, suggesting that these two proteins are encoded by different nonallelic genes. ELE1alpha is expressed in the three prostate-derived cell lines examined (PC-3, DU-145, and LNCaP), and this expression is not altered by androgen treatment. Of all rat tissues examined, ELE1alpha expression is highest in the testis. This is also the only tissue in which we could demonstrate ELE1beta expression. Both ELE1alpha and ELE1beta interact in vitro with the AR, but also with the GR and the ER, in a ligand-independent way. Overexpression of either ELE1 isoform in DU-145, HeLa, or COS cells had only minor effects on the transcriptional activity of the human AR. ELE1alpha has no intrinsic transcription activation domain or histone acetyltransferase activity, but it does interact with another histone acetyltransferase, p/CAF, and the basal transcription factor TFIIB. The interaction with the AR occurs through the ligand-binding domain and involves the region corresponding to the predicted helix 3. Mutation in this domain of leucine 712 to arginine greatly reduces the affinity of the AR for ELE1alpha but has only moderate effects on its transcriptional activity. Taken together, we have identified two isoforms of the putative coactivator ARA70/ELE1 that may act as a bridging factor between steroid receptors and components of the transcription initiation complex but which lack some fundamental properties of a classic nuclear receptor coactivator. Further experiments will be required to highlight the in vivo role of ELE1 in nuclear receptor functioning.

Entities:  

Mesh:

Substances:

Year:  1999        PMID: 9892017     DOI: 10.1210/mend.13.1.0214

Source DB:  PubMed          Journal:  Mol Endocrinol        ISSN: 0888-8809


  31 in total

1.  Promoter variants in the MSMB gene associated with prostate cancer regulate MSMB/NCOA4 fusion transcripts.

Authors:  Hong Lou; Hongchuan Li; Meredith Yeager; Kate Im; Bert Gold; Thomas D Schneider; Joseph F Fraumeni; Stephen J Chanock; Stephen K Anderson; Michael Dean
Journal:  Hum Genet       Date:  2012-06-04       Impact factor: 4.132

2.  FHL2, a novel tissue-specific coactivator of the androgen receptor.

Authors:  J M Müller; U Isele; E Metzger; A Rempel; M Moser; A Pscherer; T Breyer; C Holubarsch; R Buettner; R Schüle
Journal:  EMBO J       Date:  2000-02-01       Impact factor: 11.598

3.  Differential induction of androgen receptor transactivation by different androgen receptor coactivators in human prostate cancer DU145 cells.

Authors:  S Yeh; H Y Kang; H Miyamoto; K Nishimura; H C Chang; H J Ting; M Rahman; H K Lin; N Fujimoto; Y C Hu; A Mizokami; K E Huang; C Chang
Journal:  Endocrine       Date:  1999-10       Impact factor: 3.633

4.  Variable expression of nuclear receptor coactivator 4 (NcoA4) during mouse embryonic development.

Authors:  Alexandra Kollara; Theodore J Brown
Journal:  J Histochem Cytochem       Date:  2010-03-30       Impact factor: 2.479

5.  The androgen receptor amino-terminal domain plays a key role in p160 coactivator-stimulated gene transcription.

Authors:  P Alen; F Claessens; G Verhoeven; W Rombauts; B Peeters
Journal:  Mol Cell Biol       Date:  1999-09       Impact factor: 4.272

6.  Mifepristone inhibits GRβ coupled prostate cancer cell proliferation.

Authors:  Martin Ligr; Yirong Li; Susan K Logan; Samir Taneja; Jonathan Melamed; Hebert Lepor; Michael J Garabedian; Peng Lee
Journal:  J Urol       Date:  2012-07-21       Impact factor: 7.450

7.  Stimulation of prostate cancer cellular proliferation and invasion by the androgen receptor co-activator ARA70.

Authors:  Yi Peng; Caihong X Li; Fei Chen; Zhengxin Wang; Martin Ligr; Jonathan Melamed; Jianjun Wei; William Gerald; Michele Pagano; Michael J Garabedian; Peng Lee
Journal:  Am J Pathol       Date:  2007-12-21       Impact factor: 4.307

Review 8.  The role of coactivators and corepressors in the biology and mechanism of action of steroid hormone receptors.

Authors:  D P Edwards
Journal:  J Mammary Gland Biol Neoplasia       Date:  2000-07       Impact factor: 2.673

9.  Investigation of the relationship between prostate cancer and MSMB and NCOA4 genetic variants and protein expression.

Authors:  Liesel M FitzGerald; Xiaotun Zhang; Suzanne Kolb; Erika M Kwon; Ying Ching Liew; Antonio Hurtado-Coll; Beatrice S Knudsen; Elaine A Ostrander; Janet L Stanford
Journal:  Hum Mutat       Date:  2012-10-04       Impact factor: 4.878

10.  Pathogenesis of prostate cancer and hormone refractory prostate cancer.

Authors:  J S Girling; H C Whitaker; I G Mills; D E Neal
Journal:  Indian J Urol       Date:  2007-01
View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.